BioCryst Pb Ratio vs Graham Number Analysis

BCRX Stock

USD 7.38 0.31 4.03%

Trend analysis of BioCryst Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 12.2 M, Other Current Liabilities of 153.3 M or Total Current Liabilities of 168.4 M provides information on BioCryst Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of BioCryst Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using BioCryst Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Non Current Assets Total

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

About BioCryst Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of BioCryst Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. BioCryst Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of BioCryst Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which BioCryst currently owns. An asset can also be divided into two categories, current and non-current.

BioCryst Pharmaceuticals Balance Sheet Chart

At this time, BioCryst Pharmaceuticals' Total Liabilities is fairly stable compared to the past year. Property Plant And Equipment Gross is likely to rise to about 33.7 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 12.2 M in 2025.

Total Assets Short Long Term Debt Total Property Plant And Equipment Net Total Current Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of BioCryst Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BioCryst Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most indicators from BioCryst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 119.89 in 2025, whereas Tax Provision is likely to drop slightly above 1.9 M in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	412.7M	430.5M	441.0M	463.0M
Cost Of Revenue	6.6M	4.7M	12.3M	9.2M

Total Operating Expenses Cost Of Revenue

BioCryst Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Non Currrent Assets Other	Common Stock Total Equity	Short Term Investments	Common Stock	Other Liab	Current Deferred Revenue
Total Assets		0.7	0.86	0.87	-0.59	0.81	0.42	-0.94	0.78	0.73	0.37	0.98	0.95	0.94	0.14	0.9	0.95	0.79	0.99	-0.69	-0.03	0.93	0.67	0.93	-0.68	-0.31
Short Long Term Debt Total	0.7		0.4	0.43	-0.56	0.47	0.87	-0.56	0.74	0.66	-0.16	0.75	0.55	0.62	0.19	0.6	0.61	0.32	0.74	-0.53	-0.57	0.5	0.39	0.55	-0.41	-0.16
Other Current Liab	0.86	0.4		0.96	-0.3	0.93	0.29	-0.94	0.51	0.32	0.63	0.77	0.91	0.9	-0.04	0.84	0.93	0.93	0.82	-0.62	0.28	0.88	0.87	0.88	-0.61	-0.29
Total Current Liabilities	0.87	0.43	0.96		-0.44	0.91	0.25	-0.96	0.64	0.43	0.57	0.82	0.95	0.84	-0.04	0.76	0.88	0.87	0.84	-0.47	0.21	0.95	0.79	0.96	-0.72	-0.39
Total Stockholder Equity	-0.59	-0.56	-0.3	-0.44		-0.32	-0.22	0.47	-0.7	-0.8	-0.03	-0.69	-0.58	-0.35	0.31	-0.26	-0.37	-0.29	-0.61	0.09	0.52	-0.6	0.01	-0.59	0.57	0.42
Property Plant And Equipment Net	0.81	0.47	0.93	0.91	-0.32		0.42	-0.92	0.49	0.26	0.52	0.73	0.87	0.86	0.03	0.81	0.89	0.94	0.78	-0.59	0.11	0.84	0.9	0.86	-0.62	-0.25
Net Debt	0.42	0.87	0.29	0.25	-0.22	0.42		-0.39	0.4	0.21	-0.16	0.43	0.3	0.46	0.23	0.46	0.44	0.24	0.45	-0.42	-0.56	0.23	0.49	0.3	-0.19	-0.08
Retained Earnings	-0.94	-0.56	-0.94	-0.96	0.47	-0.92	-0.39		-0.67	-0.49	-0.46	-0.87	-0.98	-0.94	-0.08	-0.87	-0.96	-0.9	-0.92	0.58	-0.1	-0.96	-0.83	-0.97	0.68	0.41
Accounts Payable	0.78	0.74	0.51	0.64	-0.7	0.49	0.4	-0.67		0.86	-0.04	0.86	0.74	0.6	0.02	0.53	0.62	0.34	0.82	-0.35	-0.17	0.75	0.28	0.77	-0.59	-0.33
Cash	0.73	0.66	0.32	0.43	-0.8	0.26	0.21	-0.49	0.86		-0.09	0.83	0.61	0.51	0.04	0.48	0.51	0.23	0.76	-0.4	-0.3	0.61	-0.01	0.61	-0.5	-0.2
Non Current Assets Total	0.37	-0.16	0.63	0.57	-0.03	0.52	-0.16	-0.46	-0.04	-0.09		0.28	0.42	0.39	-0.07	0.41	0.42	0.62	0.27	-0.18	0.37	0.4	0.5	0.37	-0.2	-0.35
Cash And Short Term Investments	0.98	0.75	0.77	0.82	-0.69	0.73	0.43	-0.87	0.86	0.83	0.28		0.92	0.87	0.09	0.82	0.88	0.68	0.99	-0.63	-0.14	0.89	0.55	0.9	-0.69	-0.32
Common Stock Shares Outstanding	0.95	0.55	0.91	0.95	-0.58	0.87	0.3	-0.98	0.74	0.61	0.42	0.92		0.9	0.04	0.82	0.93	0.85	0.94	-0.54	0.08	0.99	0.72	0.99	-0.72	-0.43
Non Current Liabilities Total	0.94	0.62	0.9	0.84	-0.35	0.86	0.46	-0.94	0.6	0.51	0.39	0.87	0.9		0.22	0.97	1.0	0.87	0.93	-0.8	0.09	0.86	0.82	0.87	-0.56	-0.21
Other Current Assets	0.14	0.19	-0.04	-0.04	0.31	0.03	0.23	-0.08	0.02	0.04	-0.07	0.09	0.04	0.22		0.34	0.18	0.04	0.15	-0.2	-0.09	-0.01	0.16	0.01	0.25	-0.04
Other Stockholder Equity	0.9	0.6	0.84	0.76	-0.26	0.81	0.46	-0.87	0.53	0.48	0.41	0.82	0.82	0.97	0.34		0.96	0.84	0.89	-0.83	0.1	0.78	0.78	0.79	-0.46	-0.17
Total Liab	0.95	0.61	0.93	0.88	-0.37	0.89	0.44	-0.96	0.62	0.51	0.42	0.88	0.93	1.0	0.18	0.96		0.89	0.94	-0.77	0.11	0.89	0.83	0.9	-0.59	-0.24
Property Plant And Equipment Gross	0.79	0.32	0.93	0.87	-0.29	0.94	0.24	-0.9	0.34	0.23	0.62	0.68	0.85	0.87	0.04	0.84	0.89		0.75	-0.63	0.18	0.83	0.86	0.82	-0.56	-0.22
Total Current Assets	0.99	0.74	0.82	0.84	-0.61	0.78	0.45	-0.92	0.82	0.76	0.27	0.99	0.94	0.93	0.15	0.89	0.94	0.75		-0.69	-0.07	0.91	0.64	0.93	-0.68	-0.28
Short Term Debt	-0.69	-0.53	-0.62	-0.47	0.09	-0.59	-0.42	0.58	-0.35	-0.4	-0.18	-0.63	-0.54	-0.8	-0.2	-0.83	-0.77	-0.63	-0.69		-0.08	-0.48	-0.58	-0.5	0.33	-0.36
Non Currrent Assets Other	-0.03	-0.57	0.28	0.21	0.52	0.11	-0.56	-0.1	-0.17	-0.3	0.37	-0.14	0.08	0.09	-0.09	0.1	0.11	0.18	-0.07	-0.08		0.1	0.21	0.06	0.06	0.05
Common Stock Total Equity	0.93	0.5	0.88	0.95	-0.6	0.84	0.23	-0.96	0.75	0.61	0.4	0.89	0.99	0.86	-0.01	0.78	0.89	0.83	0.91	-0.48	0.1		0.68	1.0	-0.77	-0.4
Short Term Investments	0.67	0.39	0.87	0.79	0.01	0.9	0.49	-0.83	0.28	-0.01	0.5	0.55	0.72	0.82	0.16	0.78	0.83	0.86	0.64	-0.58	0.21	0.68		0.71	-0.48	-0.18
Common Stock	0.93	0.55	0.88	0.96	-0.59	0.86	0.3	-0.97	0.77	0.61	0.37	0.9	0.99	0.87	0.01	0.79	0.9	0.82	0.93	-0.5	0.06	1.0	0.71		-0.77	-0.4
Other Liab	-0.68	-0.41	-0.61	-0.72	0.57	-0.62	-0.19	0.68	-0.59	-0.5	-0.2	-0.69	-0.72	-0.56	0.25	-0.46	-0.59	-0.56	-0.68	0.33	0.06	-0.77	-0.48	-0.77		0.11
Current Deferred Revenue	-0.31	-0.16	-0.29	-0.39	0.42	-0.25	-0.08	0.41	-0.33	-0.2	-0.35	-0.32	-0.43	-0.21	-0.04	-0.17	-0.24	-0.22	-0.28	-0.36	0.05	-0.4	-0.18	-0.4	0.11

Click cells to compare fundamentals

BioCryst Pharmaceuticals Account Relationship Matchups

BioCryst Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	334.7M	588.2M	550M	517.0M	490.4M	514.9M
Short Long Term Debt Total	150.9M	593.2M	741.5M	848.7M	12.8M	12.2M
Other Current Liab	55.6M	70.0M	87.2M	126.4M	146.0M	153.3M
Total Current Liabilities	105.7M	103.7M	105.5M	150.0M	160.4M	168.4M
Total Stockholder Equity	(1.0B)	(1.2B)	(1.5B)	(455.5M)	(475.9M)	(452.1M)
Property Plant And Equipment Net	7.1M	8.7M	15.4M	20.9M	19.8M	20.8M
Net Debt	(147.4M)	88.8M	436.7M	714.5M	(91.9M)	(87.3M)
Retained Earnings	(1.0B)	(1.2B)	(1.5B)	(1.7B)	(1.8B)	(1.7B)
Accounts Payable	18.7M	27.8M	14.4M	20.9M	11.6M	7.8M
Cash	272.1M	504.4M	304.8M	110.6M	104.7M	67.2M
Non Current Assets Total	10.9M	22.0M	33.5M	21.0M	68.5M	71.9M
Cash And Short Term Investments	300.4M	514.4M	442.4M	389.0M	320.9M	336.9M
Common Stock Shares Outstanding	167.3M	179.1M	185.9M	192.2M	206.7M	217.0M
Liabilities And Stockholders Equity	(669.5M)	(512.4M)	(610.0M)	517.0M	490.4M	514.9M
Non Current Liabilities Total	248.3M	591.4M	739.1M	822.5M	806.0M	846.3M
Other Current Assets	5.5M	13.3M	14.1M	21.3M	14.0M	9.8M
Other Stockholder Equity	(1.8M)	1.1B	1.2B	1.2B	1.3B	1.4B
Total Liab	354.0M	695.1M	844.6M	972.5M	966.4M	1.0B
Property Plant And Equipment Gross	7.1M	8.7M	25.0M	19.1M	32.1M	33.7M
Total Current Assets	323.8M	566.1M	516.5M	496.0M	422.0M	443.1M
Accumulated Other Comprehensive Income	3K	177K	26K	1.3M	921K	967.1K
Short Term Debt	31.2M	1.8M	2.4M	2.6M	2.8M	2.6M
Non Currrent Assets Other	3.8M	6.5M	(33.5M)	80K	28.3M	29.8M
Common Stock Total Equity	1.1M	1.5M	1.8M	1.8M	2.1M	2.2M
Short Term Investments	28.2M	3.2M	119.5M	278.3M	216.1M	226.9M
Common Stock	1.8M	1.8M	1.9M	2.1M	2.1M	2.2M
Current Deferred Revenue	2.1M	150K	1.4M	1.2M	1.1M	1.0M
Property Plant Equipment	7.3M	7.1M	15.2M	15.4M	17.7M	18.6M
Net Receivables	8.6M	29.4M	50.6M	57.0M	79.1M	83.0M
Inventory	7.0M	15.8M	27.5M	28.7M	8.1M	4.1M
Net Tangible Assets	82.9M	109.3M	(147.0M)	(294.6M)	(265.1M)	(251.9M)
Long Term Debt	119.7M	585.5M	733.3M	811.3M	795.9M	835.7M
Retained Earnings Total Equity	(732.0M)	(840.6M)	(1.0B)	(1.2B)	(1.1B)	(1.0B)
Long Term Debt Total	28.1M	41.3M	119.7M	136.1M	156.5M	164.3M
Capital Surpluse	780.4M	877.3M	1.0B	1.1B	1.3B	745.7M
Long Term Investments	22.4M	0.0	6.8M	18.1M	20.3M	13.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
CRM	Salesforce
CRM	Salesforce

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioCryst Pb Ratio vs Graham Number Analysis

About BioCryst Balance Sheet Analysis

BioCryst Pharmaceuticals Balance Sheet Chart

Total Assets

Property Plant And Equipment Net

Total Current Assets

BioCryst Pharmaceuticals fundamental ratios Correlations

BioCryst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioCryst Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for BioCryst Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock Total Equity	+ 0.99	Common Stock Shares Outstanding
Common Stock	+ 0.99	Common Stock Shares Outstanding

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Common Stock Total Equity	- 0.96	Retained Earnings
Total Liab	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Non Current Liabilities Total	- 0.94	Retained Earnings